Efficient drug programs demand partners, outsourcing

The most efficient drug development programs will rely on contributions from a variety of companies, with partnerships and outsourcing providing unique expertise to advance new therapies, according to a new study from Tufts Center for the Study of Drug Development. The report calls on drug developers to completely reassess how they're structured.

"Moving forward, no company, big, medium or small pharma, or biotech--will develop new drugs entirely alone," said Kenneth Kaitin, director of the Tufts CSDD. "Increasingly, R&D productivity gains will depend on developers focusing on what they contribute best to the drug development value chain and partnering with organizations that provide capabilities that are too expensive to develop or maintain internally, or are outside of the company's core competencies."

- and check out the release
- here's the report from the Boston Business Journal

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.